Iran Press/ Europe: "Calculation was based on the analysis of data of volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol," the release added.
According to reports, the shot is likely to offer two years of protection against the illness.
The analysis of the Sputnik V vaccine efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases). The ratio of the placebo group to the vaccinated group is 1 to 3. Moscow Times reported.
The vaccine demonstrated 100% efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group.
As of December 14, more than 26,000 volunteers were vaccinated at 29 medical centers in Russia as part of the ongoing clinical trials. Currently, Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela, and other countries, as well as Phase II-III in India.
The Sputnik V vaccine has been developed by the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).
Alexander Ginsburg, head of the Gamaleya Research Institute of Epidemiology and Microbiology, made the bold claim as the Pfizer/BioNTech jab was rolled out Sunday in the start of the biggest vaccination effort in US history.
US-based biotechnology giant Moderna also announced that its COVID-19 vaccine has shown to be 94.5 percent effective in preventing the deadly disease.
214/205
Read More:
GPs in England offering Pfizer jab amid FDA warnings
First batch of coronavirus vaccine ships out from Pfizer plant to US states
World watches as first-mover Britain probes adverse reactions to Pfizer vaccine
